Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer

Current Opinion in Oncology

Volumn 23, Issue SUPPL. 1, 2011, Pages

  Damasceno, Margarida ^a  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

angiogenesis inhibitors; bevacizumab; breast cancer; vascular endothelial growth factor

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPOTHILONE DERIVATIVE; FULVESTRANT; IXABEPILONE; LETROZOLE; METHOTREXATE; PACLITAXEL; PLACEBO; TAXANE DERIVATIVE; VINCA ALKALOID;

ANEMIA; ANGIOGENESIS; ANOREXIA; ARTHRALGIA; ARTICLE; BLEEDING; BRAIN ISCHEMIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EMBOLISM; EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; INFECTION; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG EVALUATION, PRECLINICAL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; QUALITY OF LIFE; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79955005438     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000397417.75245.9c     Document Type: Article

References (40)

1. Ferlay J, Shin HR, Forman D, et al. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]; 2008 http:// globocan.iarc.fr. [Cited 23 June 2010].
2. Porter P. 'Westernizing' women's risks? Breast cancer in lower-income countries. N Engl J Med 2008; 358:213-216.
3. Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998; 52 (1-3): 65-77. (Pubitemid 29056086)
4. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007; 8:235-244. (Pubitemid 46291713)
5. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182. (Pubitemid 17231334)
6. Abd El-Rehim DM, Ball G, Pinder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large well characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005; 116:340-350. (Pubitemid 40993329)
7. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypesinindependent gene expression data sets. Proc Natl Acad SciUSA 2003; 100:8418-8423. (Pubitemid 36842560)
8. Beslija S, Bonneterre J, Burstein HJ, et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20:1771-1785.
9. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Breast Cancer 2010. http://www.nccn.org/professionals/physi-cian- gls/f-guidelines.asp#site. [Cited 14 April 2010].
10. Miles DW. Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer. Breast Cancer Res 2009; 11:208.
11. Tkaczuk KH. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clin Ther 2009; 31 (Pt 2):2273-2289.
12. FolkmanJ. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
13. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-676. (Pubitemid 36749215)
14. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 2000; 5 (Suppl 1):37-44. (Pubitemid 30225456)
15. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-257.
16. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of antitumour activity. Nat Rev Cancer 2008; 8:579-591.
17. Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005; 23:1782-1790. (Pubitemid 46211430)
18. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57:4593-4599. (Pubitemid 27441066)
19. Genetech Inc. AVASTIN (bevacizumab). San Francisco, CA; 2009.
20. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capeci-tabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23:792-799. (Pubitemid 46224178)
21. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57:963-969. (Pubitemid 27098025)
22. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-2676.
23. Gray R, Bhattacharya S, Bowden C, et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27:4966-4972.
24. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28:3239-3247.
25. Harbeck N, Chan A, ten Bokkel Huinink D, et al. No clinical evidence for increase in tumour malignant potential in patients (pts) with metastatic breast cancer (mBC) treated with bevacizumab (BV) and docetaxel (D) in the phase III AVADO study; 2009 [abstract 6086]. http://www.abstracts2 view.com/sabcs09/view. php?nu=SABCS09L-545. [Cited 14 April 2010].
26. O'Shaughnessy JA, Brufsky AM. RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer. Clin Breast Cancer 2008; 8:370-373.
27. Robert N, Dieras V, Glaspy J, et al. Clinical benefit rate and time to response in RIBBON-1, a randomized, double-blind, phase III trial of chemotherapy with or without bevacizumab (B) for the first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC); 2009 [abstract 6084]. http:// www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L- 1224. [Cited 15 April 2010].
28. Robert N, Dieras V, Glaspy J, et al. Phase III studies of bevacizumab (B) in combination with chemotherapy in patients with HER2-negative metastatic breast cancer (MBC): summary of selected adverse events; 2009 [abstract 6083]. http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L- 1201. [Cited 14 April 2010].
29. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2009; 27 (Suppl): 15s.
30. O'Shaughnessy D, Miles D, Gray RJ, et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). [abstract 1005]. J Clin 2010; 28 (15s).
31. Aparicio-Gallego G, Afonso-Afonso FJ, Leon-Mateos L, et al. Molecular basis of hypertension side effects induced by sunitib. Anticancer Drugs 2011; 22:1-8.
32. Mourad JJ, des Guetz G, Debbabi H, et al. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008; 19:927-934.
33. Calvo V, Ramirez N, Saura C, et al. Risk of venous and arterial thromboembolic events in patients with metastatic breast cancer treated with bevacizumab: A meta-analysis. [abstract 1043] J Clin Oncol 2010; 28 (15s).
34. Greil R, Im YH, Pienkowski T, et al. Quality of life (QoL) in patients (pts) treated with bevacizumab (BV) and taxane therapy for locally recurrent (LR) or metastatic breast cancer (mBC). Eur J Cancer Suppl 2009; 7:266.
35. Orlando L, Cardillo A, Rocca A, et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anti-Cancer Drugs 2006; 17:961-967. (Pubitemid 44350615)
36. Dellapasqua S, Bertolini F, Bagnardi V, et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008; 26:4899-4905.
37. Garcia-Saenz JA, Martin M, Calles A, et al. Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refrac-tory breast cancer. J Chemother 2008; 20:632-639.
38. Calleri A, Bono A, Bagnardi V, et al. Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin Cancer Res 2009; 15: 7652-7657.
39. Bidard FC, Mathiot C, Degeorges A, et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 2010; 21:1765-1771.
40. Naik RP, Jin D, Chuang E, et al. Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. Breast Cancer Res Treatment 2008; 107:133-138. (Pubitemid 350179580)